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Abstract
Objective:  To  evaluate  lung  functional  capacity  (FC)  for  physical  exercise  in  children  and  ado-
lescents with  sickle  cell  disease  (SCD)  through  the  six-minute  walk  test  (6MWT).
Method:  A  cross-sectional  prospective  study  was  performed  to  evaluate  the  FC  of  46  patients
with SCD  through  the  6MWT.  The  following  parameters  were  assessed:  heart  rate  (HR),  respi-
ratory  rate  (RR),  peripheral  pulse  oxygen  saturation  (SpO2),  peak  expiratory  ﬂow  (PEF),  blood
pressure  (systolic  and  diastolic),  dyspnea,  and  leg  fatigue  (modiﬁed  Borg  scale)  at  rest,  in  the
end  of  the  test,  and  ten  minutes  after  the  6MWT.  The  total  distance  walked  was  also  recorded.
For  statistical  analysis,  the  parametric  variables  were  analyzed  using  the  paired  Student’s  t-
test,  analysis  of  variance  (ANOVA),  and  Bonferroni  multiple  comparisons,  with  a  signiﬁcance
level  set  at  p  ≤  0.05.
Results:  The  46  patients  were  aged  age  9.15  ±  3.06  years,  presented  baseline  Hb  of
9.49 ±  1.67  g/dL,  and  walked  480.89  ±  68.70  m.  SCD  diagnosis  was  as  follows:  group  1-
HbSS  (n  =  20)/HbS0-thalassemia  (n  =  3)  and  group  2  -  HbSC  (n  =  20)/HbS+-thalassemia  (n  =  3).
Regarding  total  distance  walked,  patients  in  group  1  walked  a  shorter  distance  than  patients
in  group  2  (459.39  ±  57.19  vs.  502.39  ±  73.60  m;  p  =  0.032).  There  was  no  statistical  difference
regarding  PEF  in  the  three  moments  of  evaluation.  The  SpO2 in  ambient  air  and  SpO2 with  O2
differed  between  groups  1  and  2  (p  <  0.001  vs.  p  =  0.002),  as  well  as  the  RR  (p  =  0.001).
Conclusion: These  patients  showed  a  lower  FC  for  exercise  than  that  predicted  for  the  age  range
in the  literature.  Patients  diagnosed  with  HbSS/S0-thalassemia  had  a  lower  performance  in  the
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test  than  those  with  HbSC/S+-thalassemia  regarding  total  distance  walked,  RR,  and  SpO2 after
the  6MWT.
© 2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Avaliac¸ão  da  capacidade  funcional  para  o  exercício  de  crianc¸as  e  adolescentes  com
doenc¸a  falciforme  pelo  teste  da  caminhada  de  seis  minutos
Resumo
Objetivo:  Avaliar  a  capacidade  funcional  pulmonar  (CF)  para  o  exercício  físico  de  crianc¸as  e
adolescentes  com  doenc¸a falciforme  (DF)  pelo  teste  da  caminhada  de  seis  minutos  (TC6’).
Métodos:  Estudo  transversal  prospectivo  avaliando  a  CF  pelo  TC6’  de  46  pacientes  com  DF.
Foram avaliados:  frequência  cardíaca  (FC),  frequência  respiratória  (FR),  saturac¸ão  de  pulso
de  oxigênio  (SpO2),  pico  de  ﬂuxo  expiratório  (PFE),  pressão  arterial  (PA)  sistólica  e  diastólica,
dispneia e  cansac¸o em  membros  inferiores  (escala  de  Borg  modiﬁcada)  em  repouso,  ao  término
e  10  minutos  após  o  TC6’  e  a  distância  percorrida.  Análise  estatística:  test  t-Student  pareado,
análise  de  variância  e  comparac¸ões  múltiplas  de  Bonferroni,  signiﬁcância  p  ≤  0,05.
Resultados: Dos  46  pacientes,  a  média  ±  dp  da  idade  foi  9,15  ±  3,06  anos,  hemoglobina  basal
9,4 ±  1,67  g/dL  e  distância  percorrida  480,89  ±  68,70  m.  Diagnóstico  da  DF:  Grupo  1--  HbSS
(n  =  20)/HbS0-talassemia  (n  =  3);  e  Grupo  2  --  HbSC  (n  =  20)/  HbS+-talassemia  (n  =  3).  O  Grupo
1  apresentou  menor  distância  percorrida  do  que  o  Grupo  2  (459,39  ±  57,19  vs  502,39  ±  73,60m;
p  =  0,032).  Não  houve  diferenc¸a estatística  em  relac¸ão  ao  PFE.  A  SpO2 em  ar  ambiente  e  a  SpO2
com  O2 (1  L/min)  após  o  teste  foi  maior  no  Grupo  2  (p  <  0,001  e  p  =  0,002,  respectivamente).  A
FR  foi  maior  no  Grupo  1  ao  ﬁnal  do  TC6’  (p  <  0,001).
Conclusão:  Esta  amostra  apresentou  CF  para  o  exercício  abaixo  do  predito  para  a  faixa  etária
na literatura.  Os  pacientes  com  HbSS/S0-talassemia  apresentaram  desempenho  inferior  na
distância  percorrida,  FR  e  SpO2 após  o  TC6′,  comparativamente  aos  pacientes  com  HbSC/S+-
talassemia.
©  2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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ste é Introduction
Sickle  cell  anemia  (HbSS)  is  the  most  common  monogenic
hereditary disease  in  Brazil,  with  an  estimated  prevalence
of heterozygotes  for  HbS  ranging  from  2%  to  8%  in  the  gen-
eral population.1 HbSS,  the  most  severe  form  of  sickle  cell
disease (SCD)  is  a  hemoglobinopathy  resulting  from  the  sin-
gle amino  acid  substitution  of  a  glutamic  acid  for  a  valine
at the  sixth  position  of  the  beta  globin  chain,  on  chromo-
some 11,  giving  rise  to  hemoglobin  S  (HbS).2 This  alteration
in hemoglobin  is  responsible  for  the  anomalous  form  of  ery-
throcytes, leading  to  hemolytic  anemia,  endothelial  vascu-
lopathy, and  vaso-occlusive  phenomena,  followed  by  tissue
ischemia and  necrosis,  with  subsequent  organ  dysfunction,
which are  responsible  for  the  high  mortality  of  SCD.1,2 SCD
occurs when  HbS  combines  with  another  hemoglobinopathy,
such as  C,  D,  -thalassemia,  or  another  HbS.3
The  lung  is  a  major  target  organ  of  acute  and  chronic
complications in  SCD;  acute  chest  syndrome  (ACS)  is  the
second most  frequent  cause  of  hospitalization  in  this  pop-
ulation, with  high  rates  of  morbidity  and  mortality.4--6 It  is
an acute  complication  usually  triggered  by  a  clinical  picture
of infection.  It  can  be  deﬁned  by  a  combination  of  signs
and symptoms,  which  include  dyspnea,  chest  pain,  fever,
cough, and  a  new  pulmonary  inﬁltrate.7 The  proliferative
vasculopathy that  occurs  in  sickle  cell  disease  is  the  main
Ecause of  the  chronic  pulmonary  alterations  that  occur  in
these patients.8
The  chronic  alterations  and  recurrent  episodes  of  ACS
decrease the  functional  capacity  (FC)  in  patients  with  SCD.
M
T
cacLean  et  al.,9 when  assessing  lung  function  in  children
ith SCD  through  spirometry,  observed  a  restrictive  pul-
onary pattern  and  a  progressive  reduction  in  lung  volume.
nother prospective  study,10 with  patients  aged  10  to  26
ears, found  alterations  in  pulmonary  function,  with  a  pre-
ominance of  mixed  or  combined  pattern.
Thus,  the  evaluation  of  FC  should  be  part  of  outpatient
onitoring of  these  patients.  However,  studies  assessing  and
ddressing the  FC  in  children  and  adolescents  with  SCD  are
imited.11 A simple  and  effective  method  to  evaluate  the  FC
s to  apply  the  six-minute  walk  Ttest  (6MWT),  which  provides
nformation about  functional  status,  oxygen  consumption,
xercise tolerance,  and  patient  survival  according  to  test
erformance.12,13 The  6MWT  assesses  the  individual’s  sub-
aximal effort,  similar  to  the  effort  made  in  some  daily  life
ctivities, representing  their  FC  to  exercise.12
Although  the  6MWT  has  not  been  widely  studied  in
atients with  hemoglobinopathies,  especially  in  pediatric
atients, preliminary  data  suggest  that  there  may  be  a  good
orrelation among  this  test,  maximum  oxygen  uptake,  and
everity of  pulmonary  hypertension  in  adults  with  SCD.14
here  are  no  published  articles  in  the  literature  evaluat-
ng the  FC  in  children  and  adolescents  with  SCD;  thus  this
tudy aimed  to  evaluate  the  FC  to  exercise  in  children  and
dolescents with  SCD  using  the  6MWT.
um artigo Open Access sob a licença de CC BY-NC-NDethods
his  was  a  prospective  cross-sectional  study  evaluating  46
hildren and  adolescents  with  SCD  aged  between  6  and
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(-3.85 /  1.50,  p  =  0.052)  and  DBP  (-3.09/1.48,  p  =  0.119);  rest90  
8  years,  distributed  according  to  HbSS  genotype,  HbS0-
halassemia, HbSC,  and  HbS+-thalassemia.  The  children
ho were  attended  to  at  the  pediatric  hematology  outpa-
ient clinic  from  April  of  2009  to  July  of  2010  and  met  the
nclusion criteria  were  evaluated.
The  FC  of  these  patients  was  evaluated  through  the
MWT, following  the  guidelines  of  the  American  Thoracic
ociety.12 The  study  was  approved  by  the  Ethics  Committee
n Research  of  the  Escola  Paulista  de  Medicina/Universidade
ederal de  São  Paulo  (EPM/UNIFESP).  Exclusion  criteria  were
atients  with  hemodynamic  instability  or  neurological  or
rthopedic diseases  that  limited  exercise  performance.
Basal  hemoglobin  (Hb)  and  history  of  hospitalizations  for
ulmonary complications  were  collected  from  the  patients’
edical records.  The  assessment  of  body  mass  (in  kg)  and
eight (in  m)  was  performed  in  a  standardized  manner,  using
n anthropometric  digital  scale  (Filizola®).  The  classiﬁcation
f nutritional  status  was  performed  using  Z-score  distribu-
ion for  weight/age,  height/age  and  body  mass  index  (BMI).
he WHO  AnthroPlus  2007  software  of  the  World  Health
rganization (WHO)  was  used  to  obtain  the  BMI  and  Z  score
alues.15
The  6MWT  was  performed  in  a  10-meter  long  corridor,
utdoors, with  markings  at  every  meter  and  indicators  on  the
round indicating  the  beginning  and  end  of  the  trajectory.  It
as decided  to  perform  the  test  in  a  10-meter  corridor  due
o the  promising  results  in  the  ‘‘shuttle  walk  test’’,  which
lso uses  this  distance.16--20
Patients  received  theoretical  and  practical  training
egarding the  objectives  of  the  6MWT  and  how  they  should
erform it.  Each  patient  underwent  two  tests  (with  a
0-minute interval  between  them);  the  test  with  best  per-
ormance was  considered  if  the  difference  between  tests
as less  than  10%  In  case  of  a  difference  higher  than  10%,
 new  test  would  be  performed.  No  patient  had  to  perform
ore than  two  tests.
The 6MWT  was  administered  by  two  trained  physical  the-
apists. At  the  beginning  of  the  test,  the  patient  was  at  rest
or 15  to  20  minutes  and  had  fasted  for  at  least  two  hours.  At
he end  of  six  minutes,  the  patient  stopped  where  he/she
as, and  one  of  the  therapists  approached  him/her  with
 chair  and  assessment  equipment  in  order  to  record  the
otal distance  walked.  The  number  of  turns  was  counted
anually, and  a  stopwatch  (Casio®)  was  used  to  mark  the
ime.
Water was  offered  to  the  patients  before  and  after  the
MWT. All  patients  used  oxygen  during  the  test  (nasal  can-
ula 1  L/min),  regardless  of  SpO2 on  ambient  air,  in  order
o prevent  hypoxemia  during  exercise,  due  to  the  risk  of  a
aso-occlusive crisis  caused  by  SCD.
All  variables  were  assessed  at  rest,  at  the  end  of  the  test,
nd at  10  minutes  after  it.  The  following  parameters  were
easured: systolic  (SBP)  and  diastolic  (DBP)  blood  pressure
ith a  BD® sphygmomanometer;  respiratory  rate  (RR),  SpO2,
nd heart  rate  (HR)  with  a  portable  pulse  oximeter  (Dixtal®).
he peak  expiratory  ﬂow  (PEF)  was  measured  using  an  Assess
eak Flow  Meter® device;  three  measurements  were  taken
nd the  highest  was  considered.21 Dyspnea  and  lower-limb
atigue were  assessed  by  the  modiﬁed  Borg  scale.21 All
ariables were  measured  with  the  patient  in  the  sitting  posi-
ion, except  for  PEF,  which  was  measured  in  the  standing
osition.
v
H
pHostyn  SV  et  al.
To analyze  the  behavior  of  SCD  during  the  6MWT,  the  sam-
le was  divided  into  two  groups  according  to  the  disease
enotype. Group  1  consisted  of  patients  with  HbSS/HbS0-
halassemia and  group  2  consisted  of  patients  with  HbSC/
bS+-thalassemia,  as  patients  in  group  1  tend  to  have  a
ore severe  clinical  course  than  those  in  group  2.22,23
tatistical  analysis
arametric  variables  were  analyzed  by  paired  Student’s  t-
est  and  continuous  measurements  by  ANOVA  for  repeated
easures. Multiple  Bonferroni  comparisons  were  made
etween the  two  evaluation  moments,  and  values  were
onsidered statistically  signiﬁcant  when  p ≤  0.05.  Results
re shown  as  mean  ±  standard  deviation  (SD),  median
minimum-maximum),  frequency,  and  percentage.  The  sta-
istical analysis  was  performed  using  the  Statistical  Package
or Social  Sciences  (SPSS)  release  15.0.
esults
his  study  evaluated  46  patients  with  SCD  with  the
ollowing demographic  characteristics,  expressed  as
ean ±  standard  deviation  (SD):  age  9.15  ±  3.06  years;
asal Hb  9.49  ±  1.67  g/dL;  weight  30.98  ±  11.30  kg;
eight 1.34  ±  0.16  m;  BMI  16.63  ±  2.40  kg/m2;  percentile
eight/age 49.29  ±  26.57;  height/age  42.83  ±  25.92;  and
MI/age 46.86  ±  24.70.  The  Z-scores  for  all  anthropo-
etric indices  were:  weight/age  0.04  ±  1.03;  height/age
.22 ±  0.95;  and  BMI/age  0.20  ±  1.26.  The  total  distance
alked during  the  6MWT  was  480.89  ±  68.70  m.
Patients in  group  1  and  group  2  were  similar  regarding
ge, gender,  and  anthropometric  variables;  group  1  had
ower mean  Hb  values  and  higher  frequency  of  pneumonia
nd/or ACS  than  group  2  (Table  1).  The  distance  walked  by
atients in  group  1  was  signiﬁcantly  shorter  than  that  of
atients in  group  2  (459.39  ±  57.19  vs.  502.39  ±  73.60  m,
 = 0.032  - Table  1).
Analyzing  the  46  patients,  it  was  observed  that  the  car-
iorespiratory variables  (HR  and  RR)  differed  only  at  the
nd of  the  6MWT  compared  to  the  other  moments  in  time
p <  0.001).  SBP  and  DBP  decreased  signiﬁcantly  ten  minutes
fter the  end  of  the  6MWT,  when  compared  to  measurements
t the  end  of  the  test  (p  =  0.003,  p  <  0.001)  (Table  2).
There  was  no  statistical  difference  regarding  PEF  (L/min)
etween the  three  moments  in  time,  as  well  as  in  the  eval-
ation of  lower-limb  stress  and  fatigue  assessed  by  the  Borg
cale (Table  3).
Table 4  presents  the  description  of  the  variables  mea-
ured during  the  6MWT  (at  rest,  end  of  the  test  and  ten
inutes after  the  6MWT)  in  groups  1  and  2.  When  per-
orming multiple  comparisons  of  mean  differences  between
he moments  when  cardiorespiratory  and  respiratory  varia-
les were  measured  in  Groups  1  and  2,  it  was  observed
means of  measurements/standard  error;  p)  at  rest  vs.
nd of  the  6MWT  that  there  was  an  increase  in  HR  (-
0.83/2.50; p  <  0.001),  RR  (-4.50/0.56;  p  <  0.001),  SBPs. ten  minutes  after  the  end  of  the  6MWT,  a  decrease  in
R (0.76/2.93,  p  =  1),  RR  (0.41/0.70,  p  =  1),  SBP  (1.41/2.03,
 = 1)  and  DBP  (2.80/1.76,  p  =  0.343);  end  of  the  6MWT  vs.
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Table  1  Demographic  and  clinical  data  and  distance  walked  in  the  six-minute  walk  test  by  the  HbSS/S0-thalassemia  and
HbSC/S+-thalassemia  groups.
HbSS  /  S0-thalassemia
group  1
HbSC /  S+-thalassemia
group  2
p
Demographic  data
Age (years)  9.21  ±  3.45  9.08  ±  2.69  0.887
Gender (%)  56.53  (male)  52.17  (male)  0.767a
Weight  (Kg) 30.85  ±  13.31 31.11  ±  9.16 0.939
Height (m) 1.34  ±  0.18 1.34  ±  0.14 0.956
Body mass  index 16.37  ±  2.67 16.89  ±  2.13 0.472
Hb (mean  g/dL)  8.26  ±  1.33  10.70  ±  0.90  <  0.001
Hospitalizations due  to  pulmonary  complications  0.001b
PNM  %  (n)  47.82  (11)  34.78  (8)
ACS  %  (n)  26.08  (6)  0.0
ACS and  PNM  %  (n)  13.05  (3)  8.70  (2)
No complications  %  (n)  13.05  (3)  56.52  (13)
Distance  walked  (m)  459.30  ±  57.19  502.39  ±  73.6  0.032
Tests, Student’s t-test; ACS, acute chest syndrome; n, number; m, meters; PNM, pneumonias.
a chi-squared.
b likelihood ratio.
Table  2  Respiratory  and  cardiorespiratory  variables  of  children  and  adolescents  with  sickle  cell  disease  submitted  to  the
six-minute  walk  test.
Variables  Rest  End  of  test  (sixth  minute)  Ten  minutes  after  end  of  the  test  p
HR  (bpm)  91.93  ±  13.0  102.76  ±  20.3a 91.17  ±  12.1  <  0.001
SpO2 c/  O2 (%)  97.46  ±  1.9  97.20  ±  1.9  -  0.183
SpO2 AA  (%)  95.15  ±  3.3  -  95.72  ±  3.0  0.053
RR (rpm)  21.67  ±  4.4  26.17  ±  5.0a 21.26  ±  4.2  <  0.001
SBP (mmHg)  99.37  ±  11.6  103.22  ±  15.4  97.96  ±  11.6a 0.003
DBP (mmHg)  59.26  ±  10.0  62.35  ±  10.2  56.46  ±  7.9a <  0.001
bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; mmHg, millimeters of mercury; rpm, respirations per minute; RR,
respiratory rate; SBP, systolic blood pressure; SpO2 AA, pulse oxygen saturation with ambient air; SpO2 w/ O2, pulse oxygen saturation
ors.
D
T
twith oxygen (1 L/min).
aTest: analysis of variance with repeated measures, with two fact
ten  minutes  after  the  end  of  the  6MWT,  a  decrease  in
HR (11.59/2.50;  p  <  0.001),  RR  (4.91/0.56,  p  <  0.001),  SBP
(5.26/1.59, p  =  0.004)  and  DBP  (5.89/1.48,  p  <  0.001).  When
comparing rest  vs.  ten  minutes  after  the  end  of  the  6MWT,
there was  an  increase  in  SpO2 AA  (-3.65/0.53;  p  <  0.001).
When comparing  Groups  1  and  2  at  rest  vs.  six  minutes  after
the end  of  the  6MWT  there  was  an  increase  in  SpO2 with  O2
(-1.57/0.47,  p  =  0.002).
a
A
a
h
Table  3  Modiﬁed  Borg  scale  and  peak  expiratory  ﬂow  of  childre
six-minute  walk  test.
Variables  Rest  End  of  the  test  (Sixth  m
Borg  Da 0  (0-3)  0  (0-9)  
Borg LLLLa 0  (0-5)  1  (0-10)  
PEF (L/min)  223.04  ±  65.92  231.63  ±  76.65  
Borg D, Borg of dyspnea; Borg LLLL, Borg of lower limbs; L/min, liters 
Test:  analysis of variance with repeated measures, with two factors.
a Variables as median (minimum-maximum).iscussion
his  study  demonstrated  that  65.21%  of  patients  had  a  his-
ory of  hospitalizations  for  pulmonary  complications  (ACS
nd/or pneumonia).  People  with  a  history  of  recurrent
CS have  lower  peak  maximum  oxygen  consumption  (VO2)
nd greater  possibility  of  chronic  lung  injury,  which  may
ave an  important  impact  on  FC  for  exercise.11 Pulmonary
n  and  adolescents  with  sickle  cell  disease  submitted  to  the
inute)  Ten  minutes  after  end  of  the  test  p
0  (0-4)  -
0  (0-9)  -
226.63  ±  67.06  0.074
per minute; PEF, peak expiratory ﬂow.
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Table  4  Description  of  variables  at  the  moments  (at  rest,  end  of  the  test,  and  ten  minutes  after  the  test)  in  the  HbSS/HbS0
-thalassemia  and  HbSC/HbS  + -thalassemia  groups.
Diagnosis
Variable  Moment  Group  1  (n  =  23)  Group  2  (n  =  23)
Mean  SD  Mean  SD
Rest  94.61  11.93  89.26  13.73
HR (bpm)  End  of  the  test  (sixth  minute)  105.65  19.44  99.87  21.25
Ten minutes  after  end  of  test  94.39  12.13  87.96  11.48
SpO2 AA  (%)  Rest  93.13  3.55  97.17  1.07
Ten minutes  after  end  of  test  94.09  3.41  97.35  0.88
SpO2 with  O2 (%) Rest 96.70 2.30 98.22  0.74
End of  the  test  (sixth  minute) 96.39 2.25 98.00 1.13
Rest  23.30  4.33  20.04  3.84
RR (rpm)  End  of  the  test  (sixth  minute)  28.30  5.34  24.04  3.66
Ten minutes  after  end  of  test  22.65  4.32  19.87  3.66
Rest 101.74  13.02  97.00  9.80
SBP (mmHg)  End  of  the  test  (sixth  minute)  104.78  18.55  101.65  11.65
Ten minutes  after  end  of  test  98.70  12.54  97.22  10.85
Rest 57.39  10.96  61.13  8.86
DBP (mmHg)  End  of  the  test  (6th  minute)  61.74  11.14  62.96  9.27
Ten minutes  after  end  of  test  55.22  9.59  57.70  5.75
Rest 223.04  64.77  223.04  68.50
PEF (L/min)  End  of  the  test  (sixth  minute)  234.57  78.78  228.70  76.12
Ten minutes  after  end  of  test  223.70  66.83  229.57  68.65
bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; L/min, liters/minute; mmHg, millimeters of mercury; RR, respi-
ratory rate; rpm, respirations per minute; SBP, systolic blood pressure; PEF, peak expiratory ﬂow; SpO2 AA, pulse oxygen saturation with
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omplications  were  similar  to  those  reported  in  literature:
6.95% of  patients  in  group  1  had  a  history  of  hospitaliza-
ion for  pulmonary  complications  (pneumonia  and/or  ACS),
hereas  in  group  2  the  incidence  was  43.48%.  Clinical  man-
festations of  SCD,  in  general,  are  more  severe  in  patients
ith HbSS  and  HbS0-thalassemia,  and  ACS  is  more  frequent
n this  group.6,23
The  total  distance  walked  in  the  6MWT  by  healthy  chil-
ren is  inﬂuenced  by  age,  height,  and  weight:  it  is  inversely
roportional to  weight  and  directly  proportional  to  age  and
eight.24 Although  the  nutritional  status  of  the  patients  were
ithin the  mean  normal  values,  differing  from  other  stud-
es in  SCD  where  patients  tend  to  be  malnourished,25,26 the
istance walked  during  the  6MWT  was  shorter  than  that  pre-
icted for  age  and  height,27--29 meaning  that  factors  other
han weight  and  height,  such  as  hemoglobin  value  and  the
ccurrence of  ACS,  may  be  related  to  these  ﬁndings.
When  comparing  the  total  distance  walked,  patients  in
roup 2  walked  a  signiﬁcantly  longer  distance  than  those
n group  1.  These  results  may  be  related  to  the  fact  that
atients with  HbSS  and  S0-thalassemia  have  a  clinically
ore severe  form  of  the  disease,  with  lower  basal  Hb  val-
es and  greater  number  of  hospitalizations  for  pulmonary
omplications, which  may  have  also  caused  a  signiﬁcant  dif-
erence in  the  comparison  of  the  two  groups  regarding  SpO2
nd  RR  during  the  6MWT.
Liem  et  al.11 evaluated  FC  in  30  children  and  ado-
escents with  SCD  undergoing  exercise  testing,  and  found
C limitation  ranging  from  moderate  to  severe.  FC  for
o
d
rn).
xercise  was  signiﬁcantly  lower  in  children  with  a  history
f recurrent  ACS.  and  was  related  to  the  level  of  basal
b (9.5  ±  1.6  g/dL),  similar  to  values  found  in  this  study
9.49 ±  1.67  g/dL  -  Table  1).
Most  children  and  adolescents  adapt  to  the  increased  car-
iac demand  caused  by  chronic  anemia,  and  generally  have
 50%  to  75%  reduced  exercise  capacity.30 Chronic  anemia
an lead  to  lower  tissue  oxygenation,  mainly  during  exer-
ise, in  which  the  use  of  oxygen  is  increased  to  meet  the
emand for  energy.  In  SCD,  some  compensatory  mechanisms
revent this  from  occurring,  such  as  increased  heart  rate
uring exercise,  increased  systolic  volume,  and  decreased
eripheral vascular  resistance,  reducing  the  resistance  of
ickle erythrocytes  in  capillary  transit  and  oxygen  supply
o the  tissues,  thus  allowing  close  to  normal  saturation  in
he mixed  venous  blood.31,32 This  could  explain  the  present
esults of  a  signiﬁcant  increase  in  HR  at  the  end  of  the  6MWT
ithout signiﬁcant  changes  in  SpO2.
The  study  by  Campbell  et  al.32 concluded  that  the
xercise-induced  SpO2 decrease  was  more  related  to  the
egree of  anemia  and  hemolysis  than  to  previous  history
f ACS  and  severe  pain.  Lammers  et  al.33 demonstrated
hat SpO2 varies  little  during  the  6MWT  in  healthy  children,
hereas there  is  an  increase  in  HR  and  RR.  In  the  present
tudy, a  signiﬁcant  increase  in  HR,  RR  and  SpO2  with  O2 was
bserved at  the  end  of  the  6MWT.
SBP  in  patients  with  SCD  is  described  as  normal  and  DBP  as
ecreased, resulting  in  a  lower  mean  arterial  pressure.34 The
esponse observed  in  this  study,  a decrease  in  SBP  and  DBP
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ten  minutes  after  the  6MWT,  may  be  related  to  the  decrease
in HR  and  consequent  decrease  in  cardiac  output,  main-
taining vasodilation  for  a  period  of  time  after  the  exercise,
which was  also  described  in  other  studies.35,36
A  subjective  method  of  dyspnea  and  fatigue  assessment
is through  the  Borg  scale.21 The  Borg  scale  can  be  used  as  an
aid to  the  6MWT,  allowing  for  the  evaluation  of  the  degree
of respiratory  distress  according  to  the  patient’s  perception
through subjective  indices.12 In  this  study,  there  were  no
signiﬁcant changes  in  respiratory  distress  of  patients  during
the 6MWT,  which  may  have  been  due  to  the  oxygen  supplied
to patients  (nasal  cannula  1L/min)  during  the  6MWT.
When  evaluating  PEF,  there  was  no  statistical  difference
among the  three  moments  in  time  (Table  3).  Lower  PEF  in
asthmatic children  is  related  to  disease  symptoms  and  the
risk of  exacerbation.37 In  the  present  sample  of  children  with
SCD, there  was  no  difference  between  groups  1  and  2  when
PEF was  evaluated  at  rest.
Regarding  the  variables  analyzed  during  the  test,  it  was
observed that  SpO2 in  ambient  air  (AA  SpO2) and  SpO2 with  1
L/min of  O2 were  on  average  signiﬁcantly  higher  in  group  1
than in  group  2.  Signiﬁcant  differences  were  also  found  for
RR, and  higher  values  were  observed  in  group  1  regardless
of the  time  of  evaluation.  These  ﬁndings  may  be  related  to
the fact  that  pulmonary  complications  were  more  frequent
in group  1.
This is  a  novel  study;  however,  it  has  the  limitation  of
using a  10-meter  corridor  to  perform  the  6MWT,  whereas
the ATS  recommends  a  30-meter  corridor.12 Despite  the  rec-
ommendation of  the  ATS,  some  studies38--40 applied  different
lengths for  the  6MWT.  Sciurba  et  al.40 stated  that  the  length
of the  track  is  not  the  most  important  feature  of  the  6MWT.
The standardization  of  the  shuttle  walk  test  recommends
the use  of  a  10-meter  corridor,19 and  there  is  a  reference
value for  the  distance  traveled  (544.28  ±  131.13  meters)
for Brazilian  children  (mean  age  ±  SD:  11.28  ±  1.85  years).20
This  study  sample  showed  low  predicted  values  for  the  dis-
tance walked  in  the  10-meter  corridor,  when  compared  to
healthy Brazilian  children.
It  can  be  concluded  that  this  sample  of  children  and
adolescents with  SCD  had  FC  for  exercise  below  that  pre-
dicted for  the  age  range  when  compared  to  healthy  children.
Patients diagnosed  with  HbSS/S0-thalassemia  had  a  worse
performance regarding  total  distance  walked,  HR,  and  SpO2
after  6MWT  when  compared  to  patients  with  HbSC/S+-
thalassemia. It  is  suggested  that  other  studies  should  be
conducted with  similar  designs  for  evaluation  of  FC  in
patients of  this  age  group  with  SCD,  as  they  show  alterations
in FC,  which  are  related  to  the  disease  prognosis  and  quality
of life.
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